Мақаланы E-mail арқылы жіберу Relationship between Hedgehog Signaling Pathway and Drug Resistance of Poorly Differentiated Gliomas
- Авторлар: Cherepanov S.1,2, Grinenko N.2, Antonova O.2, Kurapov P.1, Shepeleva I.1,2, Chekhonin V.1,2
-
Мекемелер:
- N. I. Pirogov National Research Medical University, Ministry of Health of the Russian Federation
- V. P. Serbsky Federal Medical Research Centre of Psychiatry and Narcology, Ministry of Health of the Russian Federation
- Шығарылым: Том 164, № 3 (2018)
- Беттер: 356-361
- Бөлім: Article
- URL: https://journals.rcsi.science/0007-4888/article/view/239597
- DOI: https://doi.org/10.1007/s10517-018-3989-x
- ID: 239597
Дәйексөз келтіру
Ашық рұқсат
Рұқсат берілді
Тек жазылушылар үшін
Аннотация
The effects of Hedgehog signaling inhibitor (cyclopamine) and activator (Shh) on drug resistance of U251-MG human glioma cells and human astrocyte culture to cisplatin, temozolomide, and doxorubicin were studied. Cyclopamine and Shh modified the drug resistance of U251-MG cells but not of human astrocytes. Experiments with cyclopamine, Shh, and chemical drugs can contribute to detection of the mechanisms of signaling effects on the drug resistance processes, while the experimental data can serve as one of the criteria for choosing individual chemotherapy for patients.
Авторлар туралы
S. Cherepanov
N. I. Pirogov National Research Medical University, Ministry of Health of the Russian Federation; V. P. Serbsky Federal Medical Research Centre of Psychiatry and Narcology, Ministry of Health of the Russian Federation
Хат алмасуға жауапты Автор.
Email: cherep-rsmu@yandex.ru
Ресей, Moscow; Moscow
N. Grinenko
V. P. Serbsky Federal Medical Research Centre of Psychiatry and Narcology, Ministry of Health of the Russian Federation
Email: cherep-rsmu@yandex.ru
Ресей, Moscow
O. Antonova
V. P. Serbsky Federal Medical Research Centre of Psychiatry and Narcology, Ministry of Health of the Russian Federation
Email: cherep-rsmu@yandex.ru
Ресей, Moscow
P. Kurapov
N. I. Pirogov National Research Medical University, Ministry of Health of the Russian Federation
Email: cherep-rsmu@yandex.ru
Ресей, Moscow
I. Shepeleva
N. I. Pirogov National Research Medical University, Ministry of Health of the Russian Federation; V. P. Serbsky Federal Medical Research Centre of Psychiatry and Narcology, Ministry of Health of the Russian Federation
Email: cherep-rsmu@yandex.ru
Ресей, Moscow; Moscow
V. Chekhonin
N. I. Pirogov National Research Medical University, Ministry of Health of the Russian Federation; V. P. Serbsky Federal Medical Research Centre of Psychiatry and Narcology, Ministry of Health of the Russian Federation
Email: cherep-rsmu@yandex.ru
Ресей, Moscow; Moscow
